Clinical Trial Detail

NCT ID NCT04363242
Title A Study to Find the Maximum Tolerated Dose of SYN125 in People With Advanced Colorectal and Head and Neck Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Synermore Biologics Co., Ltd.
Indications

colorectal cancer

pharynx squamous cell carcinoma

laryngeal squamous cell carcinoma

oral squamous cell carcinoma

Therapies

SYN125

SYN004 + SYN125

Age Groups: adult senior

No variant requirements are available.